Company intelligence / Profile preview
Synphora AB
Uppsala, Uppsala County, Swedensynphora.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Synphora was founded by inventors of latanoprost, a successful prostaglandin analogue used in glaucoma treatment. The company focuses on prostaglandin-based drug development primarily through outsourcing. It currently has two clinical-stage projects including JB991 for psoriasis and a study of latanoprost for Menière’s disease. A Phase II study with Biovitrum collaboration was initiated for psoriasis treatment[1][2][5].
- Therapeutic areas
- OphthalmologyNeurologyDermatology
- Modalities
- Prostaglandin analoguesSmall molecules (e.g., latanoprost derivative JB991)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biovitrum AB — collaboration on clinical development of JB991 for psoriasis[5][6]
Beyond the preview
Go deeper on Synphora AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synphora AB.